Lanean...

Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma

New therapies, including the anti‐cytotoxic T lymphocyte antigen (CTLA)‐4 antibody, ipilimumab, is approved for metastatic melanoma. Prognostic biomarkers need to be identified, because the treatment has serious side effects. Serum samples were obtained before and during treatment from 56 patients w...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Exp Immunol
Egile Nagusiak: Nyakas, M., Aamdal, E., Jacobsen, K. D., Guren, T. K., Aamdal, S., Hagene, K. T., Brunsvig, P., Yndestad, A., Halvorsen, B., Tasken, K. A., Aukrust, P., Mælandsmo, G. M., Ueland, T.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2019
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6591141/
https://ncbi.nlm.nih.gov/pubmed/30821848
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cei.13283
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!